ProKidney (PROK)
Develops rilparencel for advanced chronic kidney disease and type 2 diabetes.
Something off on this page? Send us feedback.
Develops rilparencel, an autologous cell therapy in pivotal testing for advanced chronic kidney disease and type 2 diabetes. The program combines clinical development with manufacturing and quality operations, rather than marketed-product sales.
Rilparencel, also called REACT, is an autologous cell therapy in the PROACT 1 pivotal study for people with advanced chronic kidney disease and type 2 diabetes. The randomized, blinded, sham-controlled study evaluates a targeted patient population.
The program focuses on a U.S. registration pathway after discontinuing the overseas-focused PROACT 2. Rilparencel has FDA RMAT designation, and FDA alignment identifies eGFR slope in PROACT 1 as a potential surrogate endpoint for an accelerated-approval BLA submission.
Operations are development- and manufacturing-intensive rather than built around a marketed product. More than half of employees work in manufacturing, operations, or quality roles.
Rilparencel remains in clinical development. Its pathway depends on completing PROACT 1, the eGFR-slope result, and FDA action.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 30, 2025 | B of A Securities | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $181.6M · Total debt $3.5M · Total assets $249.0M · Shareholders' equity −$883.5M
- Revenue
- $150.0K
- Operating income
- −$48.4M
- Net income
- −$28.4M
No dividends on record.
| Institutions | 16.05% | 48.54M shares | |
|---|---|---|---|
| 76 holders · as of Jun 30, 2026 | |||
| Insiders | 4.02% | 12.14M shares | |
| 1 holder · as of Oct 22, 2024 | |||
| Strategic holders | 35.36% | 106.90M shares | |
| 1 holder · as of Jun 5, 2025 | |||
| Other | 44.57% | 134.74M shares | |
| remainder | |||
302.32M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (302.32M in the company's Sep 22, 2026 report, 148.17M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Tolerantia, LLCStrategic | 35.36% | 106.90M | filed Jun 5, 2025 |
Suvretta Capital Management, LLCInstitution | 4.08% | 12.34M A | as of Jun 30, 2026 |
Aaron CowenInsider10 percent owner | 4.02% | 12.14M A | filed Oct 22, 2024 |
Morgan StanleyInstitution | 3.26% | 9.85M A | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.72% | 5.20M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | Brian JG Pereira | director | −27,052 | $1.42 |
| Aug 19, 2026 | Brian JG Pereira | director | −250,000 | $1.44 |
| Aug 18, 2026 | Brian JG Pereira | director | −257,164 | $1.37 |
| Nov 13, 2025 | Brian JG Pereira | director | −54,333 | $2.37 |
| Nov 12, 2025 | Brian JG Pereira | director | −255,026 | $2.72 |
- Eli Lilly
Jardiance and tirzepatide target CKD-progression pathways.
- AstraZeneca (ADR)
Farxiga treats CKD in adults at risk of progression.
- Novo Nordisk (ADR)
Ozempic is approved to reduce kidney-disease risks in diabetic CKD.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ProKidney | $1.84 | +3.38% | $596.9M | — | — | 729.6 | −32.1% |
| Eli Lilly | $1,169.22 | +0.37% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| AstraZeneca (ADR) | $168.47 | +0.22% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Novo Nordisk (ADR) | $39.44 | −0.92% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Median | 25.2 | 16.2 | 4.2 | +6.4% |